Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilberto De Lima Lopes

Showing results (31-40 of 91) with videos related to

Pageof 10
Sort By:
Lung Cancer (Amsterdam, Netherlands)|June 29, 2020
In response to She et al., "Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater"Min Huang, Ralph P Insinga, Thomas Burke, et al.
BMC Cancer|August 17, 2014
Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinomaBenjamin Haaland, Akhil Chopra, Sanchalika Acharyya, et al.
Cancer Medicine|July 5, 2017
Meta-analysis of first-line therapies with maintenance regimens for advanced non-small-cell lung cancer (NSCLC) in molecularly and clinically selected populationsPui San Tan, Marcel Bilger, Gilberto de Lima Lopes, et al.
Journal of Global Oncology|September 23, 2018
ASCO Leadership Development Program: International PerspectivesRoselle De Guzman, Monica Malik, Gilberto de Lima Lopes, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Global Health Initiatives of the International Oncology CommunitySana Al-Sukhun, Gilberto de Lima Lopes, Mary Gospodarowicz, et al.
Cancer Medicine|May 3, 2017
A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanomaJoao Paulo da Silveira Nogueira Lima, Mina Georgieva, Benjamin Haaland, et al.
Immunotherapy|May 6, 2017
PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival dataPedro N Aguiar, Ramon Andrade De Mello, Peter Hall, et al.
Cancer Chemotherapy and Pharmacology|February 24, 2011
Final results of a prematurely discontinued Phase 1/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatocellular carcinomaGilberto de Lima Lopes, Jennifer S Dicksey, William P Peters, et al.
Nature Reviews. Clinical Oncology|November 15, 2022
Barriers in access to oncology drugs - a global crisisCarlos Barrios, Gilberto de Lima Lopes, Mastura Md Yusof, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancerMina Georgieva, Joao P da Silveira Nogueira Lima, Pedro Aguiar, et al.
Pageof 10

Showing results (31-40 of 91) with videos related to

Sort By:
Pageof 10
Lung Cancer (Amsterdam, Netherlands)|June 29, 2020
In response to She et al., "Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater"Min Huang, Ralph P Insinga, Thomas Burke, et al.
BMC Cancer|August 17, 2014
Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinomaBenjamin Haaland, Akhil Chopra, Sanchalika Acharyya, et al.
Cancer Medicine|July 5, 2017
Meta-analysis of first-line therapies with maintenance regimens for advanced non-small-cell lung cancer (NSCLC) in molecularly and clinically selected populationsPui San Tan, Marcel Bilger, Gilberto de Lima Lopes, et al.
Journal of Global Oncology|September 23, 2018
ASCO Leadership Development Program: International PerspectivesRoselle De Guzman, Monica Malik, Gilberto de Lima Lopes, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Global Health Initiatives of the International Oncology CommunitySana Al-Sukhun, Gilberto de Lima Lopes, Mary Gospodarowicz, et al.
Cancer Medicine|May 3, 2017
A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanomaJoao Paulo da Silveira Nogueira Lima, Mina Georgieva, Benjamin Haaland, et al.
Immunotherapy|May 6, 2017
PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival dataPedro N Aguiar, Ramon Andrade De Mello, Peter Hall, et al.
Cancer Chemotherapy and Pharmacology|February 24, 2011
Final results of a prematurely discontinued Phase 1/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatocellular carcinomaGilberto de Lima Lopes, Jennifer S Dicksey, William P Peters, et al.
Nature Reviews. Clinical Oncology|November 15, 2022
Barriers in access to oncology drugs - a global crisisCarlos Barrios, Gilberto de Lima Lopes, Mastura Md Yusof, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancerMina Georgieva, Joao P da Silveira Nogueira Lima, Pedro Aguiar, et al.
Pageof 10